Lessons from CLL17: Continuous vs Fixed-Duration Therapy in 1L CLLByNicole Lamanna, MDMarch 21st 2026
Allogeneic CAR T Azer-Cel Shows Early Activity Across B-Cell MalignanciesByAndrea Eleazar, MHSMarch 12th 2026
Zanubrutinib Offers Clinical and Cost Benefits Over Acalabrutinib in R/R CLLByAndrea Eleazar, MHSMarch 4th 2026